|
Gil Candel M, Gascon Canovas JJ, Urbieta Sanz E, Gomez Espin R, Nicolas de Prado I, Iniesta Navalon C. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2020 May;112(5):360-366. doi: 10.17235/reed.2020.6618/2019. PubMed PMID: 32338010.
AÑO: 2020; IF: 2.086
|
32338010
|
Gil-Candel M, Gascon-Canovas JJ, Urbieta-Sanz E, Rentero-Redondo L, Onteniente-Candela M, Iniesta-Navalon C. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31. PubMed PMID: 32006141.
AÑO: 2020; IF: 2.054
|
|
Iniesta-Navalon C, Gascon-Canovas JJ, Gama ZADS, Sanchez-Ruiz JF, Gutierrez-Estrada EA, De-la-Cruz-Sanchez E, Harrington-Fernandez O. Potential and clinical relevant drug-drug interactions among elderly from nursing homes: a multicentre study in Murcia, Spain. Cien Saude Colet. 2019 May 30;24(5):1895-1902. doi: 10.1590/1413-81232018245.16032017. PubMed PMID: 31166522.
AÑO: 2019; IF: 1.019
|
|
Caballero Requejo C, Urbieta Sanz E, Iniesta Navalon C, Gascon Canovas JJ. [Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?]. Aten Primaria. 2019 Mar;51(3):184-185. doi: 10.1016/j.aprim.2018.11.004. Epub 2019 Jan 17. No abstract available. Spanish. PubMed PMID: 30660438; PubMed Central PMCID: PMC6837083.
AÑO: 2019; IF: 1.087
|
|
Iniesta-Navalón C, Franco-Miguel JJ, Gascón-Cánovas JJ, Rentero-Redondo L. Effect of drug interactions involving antiretroviral drugs on viral load in HIV population. Eur J Hosp Pharm. 2016 Jul;23(4):241-243. doi: 10.1136/ejhpharm-2015-000670. Epub 2015 Jun 18. PubMed PMID: 31156857; PubMed Central PMCID: PMC6451441.
AÑO: 2016; IF: 0.718
|